Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIMBRINZA adjunctive therapy added to DUOTRAV in open-angle glaucoma or ocular hypertension
NL-OMON46879Phase 4Active, not recruiting
- Sponsor
- Novartis
- Start
- Jun 2016
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of brinzolamide + brimonidine and travoprost in ocular hypertension and open-angle glaucoma (OAG), sponsored by Novartis. Primary endpoint: Change from baseline in diurnal intraocular pressure at Week 6. Started Jun 2016; status: active, not recruiting.
02
Drugs
brinzolamide + brimonidinetravoprost
03
Conditions
ocular hypertensionopen-angle glaucoma (OAG)
Beyond the preview
Go deeper on NL-OMON46879.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46879.